Semi-Annual Changes to the NASDAQ Biotechnology Index
November 12 2004 - 6:30PM
PR Newswire (US)
Semi-Annual Changes to the NASDAQ Biotechnology Index NEW YORK,
Nov. 12 /PRNewswire/ -- The Nasdaq Stock Market, Inc. (NASDAQ(R))
(OTC:NDAQ) (BULLETIN BOARD: NDAQ) announced today the results of
the semi-annual re-ranking of the NASDAQ Biotechnology Index(R)
(NASDAQ:NBI), which will become effective with the market open on
Monday, November 22, 2004. The re-ranking will result in 11
securities being added to the Index. All securities are classified
according to the FTSE Global Classification System(TM) as
biotechnology or pharmaceutical. The securities that meet the
classification criteria then must meet other Index eligibility
criteria including listing on the NASDAQ National Market and
meeting minimum requirements for market value, average daily share
volume and seasoning as a public company. The Index is ranked on a
semi-annual basis in May and November. For more information about
the NASDAQ Biotechnology Index, including eligibility criteria,
visit http://www.nasdaq.com/. All securities being added to the
Index will be phased into NASDAQ's Opening Cross effective Tuesday,
November 16, 2004. As a result of the re-ranking, Biopure
Corporation (NASDAQ:BPUR) and IDEXX Laboratories, Inc.
(NASDAQ:IDXX) will be removed from the Index. The NASDAQ
Biotechnology Index is the basis for the iShares Nasdaq
Biotechnology Index(SM) Fund (AMEX:IBB), which seeks investment
results that generally correspond to the price and yield
performance of the NASDAQ Biotechnology Index before fees and
expenses. In addition, options based on the NASDAQ Biotechnology
Index and the iShares Nasdaq Biotechnology Index Fund trade on
various exchanges. NASDAQ(R) is the largest electronic screen-based
equity securities market in the United States. With approximately
3,300 companies, it lists more companies and, on average, trades
more shares per day than any other U.S. market. It is home to
companies that are leaders across all areas of business including
technology, retail, communications, financial services,
transportation, media and biotechnology. NASDAQ is the primary
market for trading NASDAQ listed stocks. For more information about
NASDAQ, visit the NASDAQ Web site at http://www.nasdaq.com/ or the
NASDAQ Newsroom at http://www.nasdaq.com/newsroom/. The FTSE Global
Classification System is compiled by FTSE International Limited.
FTSE(TM) is a trademark of the London Stock Exchange Plc and The
Financial Times Limited and is used by FTSE International Limited
under license. iShares are distributed by SEI Investments
Distribution Co. Barclays Global Fund Advisors serves as an advisor
to iShares and is a subsidiary of Barclays Global Investors, N.A.,
neither of which is affiliated with SEI. For a prospectus, call
1-800-iSHARES (1-800-474-2737). IShares are not FDIC Insured. Have
No Bank Guarantee. May Lose Value. Company Briefs Bone Care
International, Inc. (NASDAQ:BCII) is a pharmaceutical company that
discovers, develops and commercializes improved vitamin D-hormone
therapies. The company's therapies treat secondary
hyperparathyroidism in patients with kidney disease, osteoporosis,
psoriasis, and certain cancers. Bioenvision, Inc. (NASDAQ:BIVN) is
a biopharmaceutical company primarily focused on the research and
development of products and technologies for the treatment of
cancer. The company also performs research on anti-immune diseases.
Corgentech Inc. (NASDAQ:CGTK) is a biopharmaceutical company that
discovers, develops, and commercializes therapeutics called
transcription factor decoys, or TF decoys. The company focuses on
TF decoys for the treatment of cardiovascular disease, inflammatory
disease, and cancer. Cytokinetics, Incorporated (NASDAQ:CYTK) is a
biopharmaceutical company that combines life sciences and
information technologies to accelerate and enhance the productivity
of drug discovery and development. The company focuses on the novel
small molecule drugs that specifically target the cytoskeleton, a
complex, dynamic framework that impacts all aspects of cell
functions. Discovery Laboratories, Inc. (NASDAQ:DSCO) is a
biopharmaceutical company that develops and commercializes
medically novel therapeutics for critical care. The company is
focusing on diseases of the lung, with initial emphasis on the
treatment of neonatal conditions. Discovery is also developing
pharmaceuticals to treat acute respiratory distress syndrome/acute
lung injury and cystic fibrosis. Eyetech Pharmaceuticals, Inc.
(NASDAQ:EYET) is a biopharmaceutical company that develops and
commercializes novel therapeutics to treat diseases of the eye. The
company's initial focus is on diseases affecting the back of the
eye, particularly the retina. Eyetech is developing a product for
the treatment of the wet form of age-related macular degeneration,
and for diabetic macular edema. GTx, Inc. (NASDAQ:GTXI) discovers,
develops, and commercializes therapeutics primarily related to the
treatment of serious men's health conditions. The company's drug
discovery and development programs are focused on small molecules
that selectively modulate the effects of estrogens and androgens,
two essential classes of hormones. GTx is currently developing
products for prostate cancer. NitroMed, Inc. (NASDAQ:NTMD) is a
pharmaceutical company that discovers, develops, and seeks to
commercialize proprietary pharmaceuticals based on the therapeutic
benefits of the naturally occurring molecule nitric oxide. The
company's research and development efforts focus on major diseases
that are characterized by a deficiency in nitric oxide, such as
cardiovascular and inflammatory diseases. Rigel Pharmaceuticals,
Inc. (NASDAQ:RIGL) discovers and develops novel, small molecule
drugs in four lead product development programs: allergy/asthma,
autoimmune disorders, hepatitis C, and cancer. Santarus, Inc.
(NASDAQ:SNTS) is a pharmaceutical company focused on acquiring,
developing, and commercializing proprietary products for the
prevention and treatment of gastrointestinal diseases and
disorders. The primary focus of the company is the development and
commercialization of next generation proton pump inhibitor-PPI
products. Third Wave Technologies, Inc. (NASDAQ:TWTI) provides
products used in the analysis of genetic variations. The company's
genetic analysis platform, the Invader Operating System, includes
tests for genetic mutations associated with immune response, drug
metabolism, and predisposition to blood clots. The company's tests
may be used for diagnosis and patient treatment or for drug
discovery and development. DATASOURCE: NASDAQ CONTACT: Wayne Lee,
+1-301-978-4875, or Issuer and Investor Contact: Lisa Chaney,
+1-301-978-8281, both of NASDAQ Web site: http://www.nasdaq.com/
http://www.nasdaqnews.com/
Copyright
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From May 2024 to Jun 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2023 to Jun 2024